These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 24379039)
1. Polyarthritis caused by methimazole in two Japanese patients with graves' disease. Nihei H; Tada H; Naruse Y; Izawa M; Kato M; Okuno H; Nakamura A; Ishizu K; Hamajima T; Tajima T J Clin Res Pediatr Endocrinol; 2013; 5(4):270-2. PubMed ID: 24379039 [TBL] [Abstract][Full Text] [Related]
2. Migratory polyarthritis as an adverse effect of thiamazole use in a 13-year-old girl with Graves' disease. Janson JA; de Laat P; Draaisma JM J Pediatr Endocrinol Metab; 2015 Sep; 28(9-10):1169-71. PubMed ID: 25968432 [TBL] [Abstract][Full Text] [Related]
3. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Takata K; Kubota S; Fukata S; Kudo T; Nishihara E; Ito M; Amino N; Miyauchi A Thyroid; 2009 Jun; 19(6):559-63. PubMed ID: 19445623 [TBL] [Abstract][Full Text] [Related]
4. [Relationship between methimazole and antineutrophil cytoplasmic antibody-positive vasculitis]. Chen LQ; Zhang XL; Wu HY; Guo S; Li XZ Zhonghua Er Ke Za Zhi; 2008 Jun; 46(6):446-9. PubMed ID: 19099784 [TBL] [Abstract][Full Text] [Related]
5. [Severe polyarthritis as a rare adverse effect associated with methimazole therapy in a patient with Graves' disease]. Caballero Mora FJ; Muñoz Calvo MT; López Robledillo JC; Argente J An Pediatr (Barc); 2011 Jul; 75(1):74-5. PubMed ID: 21441081 [No Abstract] [Full Text] [Related]
6. Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU). Kubota S Intern Med; 2016; 55(22):3235-3237. PubMed ID: 27853063 [TBL] [Abstract][Full Text] [Related]
7. Use of antihistamines after serious allergic reaction to methimazole in pediatric Graves' disease. Toderian AB; Lawson ML Pediatrics; 2014 May; 133(5):e1401-4. PubMed ID: 24777217 [TBL] [Abstract][Full Text] [Related]
8. The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant. Kimura M; Seki T; Ozawa H; Ishihara T; Komatsu M; Tajiri S; Yanagi H; Nishina M; Noh JY; Fukagawa M; Takagi A Endocr J; 2013; 60(3):383-8. PubMed ID: 23154533 [TBL] [Abstract][Full Text] [Related]
9. Neutropenia Occurs More Often Under Carbimazole than Under Methimazole Treatment in Pediatric Graves' Disease Patients. Schempp V; Cebeci AN; Reinauer C; Woelfle J; Dörr HG; Roosen MT; Gohlke J; Gohlke B Thyroid; 2024 Jun; 34(6):735-743. PubMed ID: 38613811 [No Abstract] [Full Text] [Related]
10. Acute pancreatitis induced by methimazole in a patient with Graves' disease. Yang M; Qu H; Deng HC Thyroid; 2012 Jan; 22(1):94-6. PubMed ID: 22136208 [TBL] [Abstract][Full Text] [Related]
11. Antithyroid Arthritis Syndrome: A Case Report and Review of the Literature. Takaya K; Kimura N; Hiyoshi T Intern Med; 2016; 55(24):3627-3633. PubMed ID: 27980264 [TBL] [Abstract][Full Text] [Related]
12. Acute pancreatitis and parotitis induced by methimazole in a patient with Graves' disease. Taguchi M; Yokota M; Koyano H; Endo Y; Ozawa Y Clin Endocrinol (Oxf); 1999 Nov; 51(5):667-70. PubMed ID: 10594530 [TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism. Sato S; Noh JY; Sato S; Suzuki M; Yasuda S; Matsumoto M; Kunii Y; Mukasa K; Sugino K; Ito K; Nagataki S; Taniyama M Thyroid; 2015 Jan; 25(1):43-50. PubMed ID: 25178068 [TBL] [Abstract][Full Text] [Related]
14. Central nervous system vasculitis after starting methimazole in a woman with Graves' disease. Tripodi PF; Ruggeri RM; Campennì A; Cucinotta M; Mirto A; Lo Gullo R; Baldari S; Trimarchi F; Cucinotta D; Russo GT Thyroid; 2008 Sep; 18(9):1011-3. PubMed ID: 18788922 [TBL] [Abstract][Full Text] [Related]
15. Perinuclear antineutrophil cytoplasmic antibody-associated vasculitis in a patient with Graves' disease treated with methimazole. Bilu Martin D; Deng A; Gaspari A; Pearson F Skinmed; 2006; 5(6):302-5. PubMed ID: 17086001 [TBL] [Abstract][Full Text] [Related]
17. The relation of initial methimazole dose to the incidence of methimazole-induced agranulocytosis in patients with Graves' disease. Tsuboi K; Ueshiba H; Shimojo M; Ishikawa M; Watanabe N; Nagasawa K; Yuasa R; Yoshino G Endocr J; 2007 Feb; 54(1):39-43. PubMed ID: 17053291 [TBL] [Abstract][Full Text] [Related]
18. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease. Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan. Huang CN; Hsu TC; Chou HH; Tsay GJ J Formos Med Assoc; 2004 Apr; 103(4):274-9. PubMed ID: 15175822 [TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Otsuka F; Noh JY; Chino T; Shimizu T; Mukasa K; Ito K; Ito K; Taniyama M Clin Endocrinol (Oxf); 2012 Aug; 77(2):310-5. PubMed ID: 22332800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]